Objective: We aimed to investigate the association between serum levels of ghrelin and brain-derived neurotrophic factor (BDNF) with MetS and its components in premenopausal women.
DOI: 10.1093/labmed/lmx087 resistance and hypertension in obese people. 11, 12 But its role in the progress of MetS is not yet fully identified.
Brain derived neurotrophic factor (BDNF) is a member of the neurotrophic factor family, which plays a key role in regulating the survival, growth, and maintenance of neurons. 13 It is released from the human brain, and cerebral output of BDNF is negatively regulated by high plasma glucose levels. 14 BDNF is involved in glucose metabolism and eating behavior, 15, 16 and its abnormal levels may be contributors in the pathogenesis of metabolic diseases including type 2 diabetes, obesity, and atherosclerosis. Lower systemic levels of BDNF have been reported in obese or type 2 diabetes patients, 14, 17 and there is further evidence that ghrelin has neuro-protective effects that may influence BDNF gene expression. 17 The occurrence of MetS and its subsequent adverse outcomes has motivated an active search for novel risk factors. The hormones that contribute to the body's balance of energy are flagged as potential risk factors for MetS. This study aims to investigate the association between serum levels of ghrelin and BDNF with MetS and its components.
Materials and Methods

Participants
This case control study was performed from January to June 2015. Eighty-six women aged 30 to 50 years participated and 43 participants had MetS, according to the ATP (III) criteria, and another 43 BMI-matched women without MetS served as the healthy control group. Participants were recruited by the convenience sampling method from the nutrition counseling clinic prior to receiving treatment. The study was approved by the Ethical Committee of Tabriz University of Medical Sciences, Tabriz, Iran, and a written informed consent was obtained from each participant.
Individuals included in MetS group had at least 3 of 5 ATP (III) criteria as follows: abdominal obesity, a WC more than 88 cm, serum triglyceride (TG) ≥ 150 mg/dl, high-density lipoprotein cholesterol (HDL-C) ≤ 50 mg/dl, blood pressure ≥ 130/85 mm Hg, fasting blood glucose (FBG) ≥ 100 mg/dl. Subjects were excluded from the study for myriad reasons, including: a body mass index (BMI) ≥ 40 kg/m 2 , smoking, excessive consumption of alcohol, infectious and chronic inflammatory diseases, a history of psychiatric diseases, receiving anti-obesity, anti-inflammatory, anti-hypertensive, corticosteroid and estrogen drugs and contraceptives during the study period, thyroid disorders, endocrine diseases, pregnancy and breast-feeding, menopause and diet therapy during the 3 months prior to the study.
Anthropometric and Blood Pressure Assessments
Anthropometric measurements including height, weight, WC and hip circumference were assessed by an expert prior to the study. Body weight was measured by means of a digital scale, with the examinee wearing a light gown. Height was measured barefoot using a wall-mounted stadiometer to the nearest 0.5 cm. BMI was calculated as body weight (kg) divided by the square of height (m 2 ). WC was measured by tape measure at the midpoint between the lower costal margin and iliac crest to the nearest 0.5 cm. Hip circumference was measured around the widest portion of the buttocks. Waist-to-hip ratio (WHR) was calculated as waist measurement divided by hip measurement. Blood pressure was measured with a calibrated sphygmomanometer, after 5-minute rest in a sitting position. Blood pressure values were estimated as the mean of 2 readings.
Biochemical Assessment
Five ml venous blood was collected after an overnight fast. Whole blood was centrifuged at 2000 rpm for 10 min at 4°C, and then serum samples were separated and stored at -70°C until analysis.
Serum levels of total cholesterol (TC), HDL-C and TG were evaluated by enzymatic colorimetric methods with a commercially available kit (Pars Azmone, Tehran, Iran) on an automatic analyzer (Abbott, model Alcyon 300, USA). Serum LDL-C was calculated by Friedewald equation. 18 FBG was determined by the glucose oxidase method. Insulin levels were measured by insulin ELISA kit (Monobind Inc, Lake Forest, CA) and the homeostasis model assessment (HOMA-IR) was calculated according to the formula: fasting insulin (microU/L) × fasting glucose (nmol/L)/22.5. Ghrelin and BDNF levels were measured using commercially available ELISA kits (Hangzhou Eastbiopharm CO, LTD) with a sensitivity of 0.05 to 10 ng/ml. All the assays were run in duplicates with an average intra-assay variation coefficient of <10%, without any notable interference and indicated as ng/ml.
Statistical Analyses
Continuous data of the study were presented as mean ± standard deviation (SD) and proportional data as frequency
(%). Independent sample t-test was used for the assessment of differences between the 2 groups. Spearman's coefficients correlations were performed for associations between ghrelin and BDNF and also between BDNF and MetS components. Pearson's coefficients correlations were used to find association of serum ghrelin with MetS components. Data analysis was performed by SPSS 22 Software (IBMSPSS statistics, Chicago, IL) and P-values less than 0.05 were considered statistically significant.
Results
Demographic Characteristics and Serum Metabolic Parameters
As shown in Table 1 , the average age of MetS and control participants were 38.57 ± 6.56 and 35.91 ± 5.71 yrs respectively (P = 0.04). As expected, mean WHR, SBP and DBP were significantly higher in the MetS group when compared with the control group (all, P = 0.01). Participants with MetS had significantly higher levels of TG, FBS, insulin, HOMA-IR and lower concentrations of HDL-C than the controls ( Table 1) .
Serum Levels of Ghrelin and BDNF
As shown in Figure 1 , participants with MetS had significantly lower levels of ghrelin when compared with the control group (1.93 ± 0.54 vs 2.34 ± 0.39 ng/ml) (P < 0.0001). Also, serum levels of BDNF were significantly lower in the MetS group (6.83 ± 2.20 ng/ml) than in the controls (8.59 ± 2.10 ng/ml) (P < 0.0001).
Correlation of Serum Levels of Ghrelin and BDNF With MetS Components
As shown in Table 2 , serum levels of ghrelin were negatively and significantly associated with serum levels of TG (r = -0.31, P = 0.006), FBS (r = -0.32, P = 0.003) and positively with serum HDL-C (r = 0.27, P = 0.02). There was no significant correlation between serum levels of ghrelin with other components of the lipid profile, serum insulin, HOMA-IR, blood pressure, WC and WHR ( Table 2) . 
Figure 1
Serum BDNF and ghrelin levels in MetS (n = 43) and control (n = 43) groups.
As shown in Table 2 , there was significant negative correlation between serum BDNF levels with serum levels of TG (r = -0.41, P < 0.0001), FBS (r = -0.32, P = 0.003), insulin (r = -0.33, P = 0.003) and HOMA-IR (r = -0.39, P < 0.0001). A significant positive correlation was also observed between BDNF levels and serum HDL-C (r = 0.39, P < 0.0001).
Association of Serum Ghrelin and BDNF
There was significant positive correlation between serum ghrelin and BDNF levels (r = 0.54, P < 0.0001) ( Figure 2 ).
Discussion
Ghrelin is a gastric hormone and BDNF belongs to neurotrophic factors. Animal model studies have indicated that alterations in the concentration of both proteins could change metabolic parameters on a biological level. Depletion or reduction of BDNF leads to an obese phenotype, increased body weight and fat content, insulin resistance, hyperinsulinemia, impaired glucose tolerance and lipid profile in mice. 19 Whereas BDNF administration reduces obesity and metabolic syndrome-like measures, including energy intake, body weight, body fat, lean mass, and serum metabolic indices such as glucose, TG and insulin. 20 A very recent study has also shown that ghrelin deletion aggravates adiposity and inflammation in adipose tissues, and also insulin resistance, 21 while chronic administration of ghrelin regulates plasma glucose and normalizes insulin levels in rats. 22 Hence, in the current study, we investigated the association between serum levels of ghrelin and BDNF with MetS and its components.
In the present study, patients with MetS had significantly lower levels of BDNF when compared with the healthy subjects, and the BDNF level was associated with several components of MetS. Hypo-neurotrophinemia is a known characteristic of patients with MetS. 23 Decreased levels of BDNF and its relationship with several risk factors of MetS and cardiovascular disorders have been shown in patients with acute coronary syndrome and MetS. [24] [25] [26] In contrast, there is other evidence that indicates higher levels of neurotrophins in people with MetS and T2DM. [27] [28] [29] [30] Neurotrophic hypothesis proposed in recent years by Hristova 31 suggests that neurotrophins play different roles in the early and final stages of MetS. According to this hypothesis, neurotrophin levels increase in response to inflammation in the early stages of MetS, which is a disease that presents with mild and progressive inflammation. 23 Nevertheless, neurotrophin levels reduce the progression of the disease and increase MetS parameters due to the impact of pro-inflammatory cytokines. 23 What's more, serum levels of ghrelin in patients with MetS were significantly lower when compared with the control group. Serum ghrelin was also inversely associated with serum levels of TG and FBS and positively with HDL-C. The results are in agreement with findings from previous studies. In a very recent study, Kheirouri et al showed that obese women had a lower ghrelin level when compared with women considered to be of a normal weight. 32 Ukkola et al, in a cohort study including 1,037 middle-aged men and women, showed that ghrelin levels were significantly lower in patients with MetS than in healthy subjects among both sexes. This decline was in proportion to an increased number of metabolic abnormalities. In this study, low plasma ghrelin has been indicated as a significant predictor of MetS. 33 Low plasma ghrelin levels have also been reported in obese patients with T2DM compared with non-obese patients. 34, 35 In a cohort study, Poykko et al con-
cluded that low ghrelin were independently associated with diabetes.
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The exact mechanism involved in the decline of ghrelin in patients with MetS is unknown, but some theories have been proposed. For example, hyperinsulinemia and hyperglycemia have been suggested as inhibitors of ghrelin secretion. 33, 36 In both humans and rats, the main source of circulating ghrelin is alpha-like A cells from the stomach which have some structural similarities to pancreatic alpha cells such as the presence of dense secretory granules. 37 Evidence shows that ghrelin secretion is not affected by expansion of the stomach. 34 However, hypoglycemia, caused by insulin, leads to increased expression of ghrelin mRNA in stomach. 35 When put together, these results indicate that a system may be present in ghrelin-producing cells that responds to plasma glucose concentrations. Therefore, increased glucose and food intake can lead to a rapid decline in circulating ghrelin concentrations. 36 On the other hand, it seems that the reduction in basal ghrelin secretion in response to increasing energy reserves is a negative in terms of helping reduce the use of further energy. In addition, ghrelin levels are reduced after food intake in obese subjects. 38 Hyperglycemia and hyperinsulinemia due to insulin resistance in MetS patients coupled with the negative association of ghrelin with FBS and insulin resistance provides further evidence to support this idea.
In the current study, ghrelin was negatively associated with TG and positively related to HDL-C. Purnell et al suggested that ghrelin is concentrated in lipid particles containing HDL-C and that this may indicate the role of HDL-C particles as carriers of ghrelin in the blood stream. 39 Further, Rodriguez et al have demonstrated that both forms of ghrelin (acylated and non-acylated) lead to lipid accumulation in adipocytes. 40 In fact, ghrelin in humans causes an increase in adiposity 40 and plays a significant role in lipid metabolism in adipose tissue, the liver and skeletal muscle. Moreover, total ghrelin has a strong tendency to store fat in the liver and stimulates lipogenesis by direct acting on adipocytes. 41, 42 These conditions may contribute to the reduction of circulating levels of triglycerides. However, the evidence of interaction of ghrelin and lipid profiles is very limited and warrants further study.
A novel finding from current study is the strong, positive association between serum levels of BDNF and ghrelin. Given the little evidence available, we refer to 2 possible mechanisms to explain this association. First, there is evidence concerning the effect of ghrelin on BDNF gene expression in animal models. 43 Studies have shown that the activation of the MEK/ERK pathway leads to increased BDNF expression. 44 Lee et al reported that ghrelin has neuroprotective effects by increasing BDNF level after spinal cord injury with increasing the level of ERK-dependent BDNF expression, which is mediated by the ghrelin receptor. 43 The second possible mechanism in this area refers to inflammation and inflammatory mediators. Studies have shown that inflammatory responses and inflammatory mediators produced in the body are effective in changing cerebral and serum BDNF levels. 45, 46 Animal models indicate that chronic stress and high levels of proinflammatory cytokines cause decreased expression of BDNF mRNA in the hippocampus. 47 Both in vivo and in vitro evidence suggests that ghrelin inhibits inflammatory responses and oxidative stress. 43 Inhibition of TNF-α, IL-6 and nitric oxide production in peritoneal macrophages and human vein endothelial cells and arthritis in rats is some of the evidence. 48, 49 Therefore, we speculate that reduced levels of ghrelin leads to increased inflammation and subsequently to decreased levels of BDNF. The evidence is very limited in this area and correct understanding of this relationship requires further study.
In this study, a significant inverse correlation was observed between serum BDNF levels and serum insulin, FBS and HOMA-IR. In this regard, our results were in agreement with the results of Karczewska-Kupczewska et al 50 and in disagreement with findings from Fujinami et al 51 and Boyuk et al. 30 Althoughthe main reasons for these differences could not be fully explained, different degrees of obesity and overweight and even racial differences among subjects, as well as the characteristics of the studied serum or plasma may affect the interpretation of results across the different studies. 51 In conclusion, in this study BDNF and ghrelin levels were shown to be lower in MetS individuals. Both peptides had positive association with circulating HDL-C and potently intercorrelated. BDNF had a negative association with HOMA-IR, serum insulin, TG and FBS. Furthermore, ghrelin had an inverse association with circulating serum level of 
Figure 2
Correlation between serum ghrelin and BDNF levels.
TG and FBS. The results suggest that lower concentrations of both proteins may biologically associate with clusters of metabolic abnormalities. In addition, interrelated hormonal and neurotrophic changes may have a role in the development of MetS and major CVD risk factors. LM
